🔗 Visit the ClinicalTrials.gov page for NCT01154049
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant. | Front Immunol | 2015 | 0.85 |
| 2 | Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults. | Vaccine | 2015 | 0.83 |
| 3 | Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. | Hum Vaccin Immunother | 2013 | 0.82 |
| 4 | Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons? | Front Immunol | 2015 | 0.81 |
| 5 | Development of a schistosomiasis vaccine. | Expert Rev Vaccines | 2016 | 0.79 |
| 6 | Still hope for schistosomiasis vaccine. | Hum Vaccin Immunother | 2015 | 0.78 |